162 related articles for article (PubMed ID: 33356073)
21. Sepsis During Immunosuppression for Sight-threatening Uveitis: The Flip side.
Jones N
Ocul Immunol Inflamm; 2018; 26(2):324-327. PubMed ID: 27540908
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.
Bhat P; Cervantes-Castañeda RA; Doctor PP; Anzaar F; Foster CS
Ocul Immunol Inflamm; 2009; 17(3):185-90. PubMed ID: 19585361
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression.
Becker MD; Wertheim MS; Smith JR; Rosenbaum JT
Ocul Immunol Inflamm; 2005; 13(4):289-93. PubMed ID: 16159719
[TBL] [Abstract][Full Text] [Related]
25. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.
Baker KB; Spurrier NJ; Watkins AS; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2006 Dec; 90(12):1481-5. PubMed ID: 16914474
[TBL] [Abstract][Full Text] [Related]
26. Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.
Reddy AK; Miller DC; Sura AA; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan B; Vedhanayaki R; Lim LL; Suhler EB; Doan T; Al-Dhibi HA; Goldstein DA; Arellanes-Garcia L; Acharya NR
J Ophthalmic Inflamm Infect; 2023 Jun; 13(1):29. PubMed ID: 37294447
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis.
Hedayatfar A; Falavarjani KG; Soheilian M; Elmi Sadr N; Modarres M; Parvaresh MM; Naseripour M; Rohani M; Almasi M; Chee SP
Ocul Immunol Inflamm; 2017 Jun; 25(3):308-314. PubMed ID: 27379567
[TBL] [Abstract][Full Text] [Related]
28. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
29. [Immunosuppressive therapy in severe or chronic pediatric uveitis: Review of the literature].
Stolowy N; Zanin E; Comet A; Jurquet AL; Benso C; Matonti F; Retornaz K; Kaplanski G; Denis D
J Fr Ophtalmol; 2021 Feb; 44(2):252-258. PubMed ID: 33423814
[TBL] [Abstract][Full Text] [Related]
30. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
[TBL] [Abstract][Full Text] [Related]
31. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil in the treatment of uveitis in children.
Doycheva D; Deuter C; Stuebiger N; Biester S; Zierhut M
Br J Ophthalmol; 2007 Feb; 91(2):180-4. PubMed ID: 16825275
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents].
Caspers-Velu LE
Bull Soc Belge Ophtalmol; 2001; (279):49-59. PubMed ID: 11344715
[TBL] [Abstract][Full Text] [Related]
34. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
35. General principles for the treatment of non-infectious uveitis.
Díaz-Llopis M; Gallego-Pinazo R; García-Delpech S; Salom-Alonso D
Inflamm Allergy Drug Targets; 2009 Sep; 8(4):260-5. PubMed ID: 19754409
[TBL] [Abstract][Full Text] [Related]
36. Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
Kong CL; Kelly NK; Sundararajan M; Rathinam SR; Gonzales JA; Thundikandy R; Vedhanayaki R; Kanakath A; Murugan B; Doan T; Goldstein D; Al-Dhibi HA; Acharya NR
Ocul Immunol Inflamm; 2022 Jan; 30(1):198-202. PubMed ID: 32779952
[TBL] [Abstract][Full Text] [Related]
37. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
Czaja AJ; Carpenter HA
J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
[TBL] [Abstract][Full Text] [Related]
38. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011).
Wang A; Smith JR; Creevy KE
J Small Anim Pract; 2013 Aug; 54(8):399-404. PubMed ID: 23879827
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis.
Ucar D; Esatoglu SN; Cerme E; Batu-Oto B; Hamuryudan V; Seyahi E; Melikoglu M; Fresko I; Ozyazgan Y; Hatemi G
Rheumatol Int; 2023 Nov; 43(11):2099-2106. PubMed ID: 37592141
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil in patients with Crohn's disease.
Fickert P; Hinterleitner TA; Wenzl HH; Aichbichler BW; Petritsch W
Am J Gastroenterol; 1998 Dec; 93(12):2529-32. PubMed ID: 9860419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
